Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - GT Biopharma, Inc.Financial_Report.xls
10-K - OXIS ANNUAL REPORT 2011 - GT Biopharma, Inc.oxis10k2011.htm
EX-23.1 - CONSENT OF SELIGSON & GIANNATTASIO, LLP - GT Biopharma, Inc.ex231.htm
EX-31.1 - EXHIBIT 31.1 - GT Biopharma, Inc.ex311.htm


Exhibit 32.1


CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of OXIS International, Inc. (the “Company”) for the year ended December 31, 2011, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), David Saloff, Chief Executive Officer and acting Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated:  April 16, 2012
By: /s/ David Saloff                                           
 
David Saloff
 
Chief Executive Officer and
acting Chief Financial Officer
   

This certification accompanies each Report pursuant to § 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of §18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.